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ABSTRACT Although proteases related to the interleukin
1,8-converting enzyme (ICE) are known to be essential for
apoptotic execution, the number of enzymes involved, their
substrate specificities, and their specific roles in the charac-
teristic biochemical and morphological changes of apoptosis
are currently unknown. These questions were addressed using
cloned recombinant ICE-related proteases (IRPs) and a cell-
free model system for apoptosis (S/M extracts). First, we
compared the substrate specificities of two recombinant hu-
man IRPs, CPP32 and Mch2ca. Both enzymes cleaved poly-
(ADP-ribose) polymerase, albeit with different efficiencies.
Mch2a also cleaved recombinant and nuclear lamin A at a
conserved VEID4NG sequence located in the middle of the
coiled-coil rod domain, producing a fragment that was indis-
tinguishable from the lamin A fragment observed in S/M
extracts and in apoptotic cells. In contrast, CPP32 did not
cleave lamin A. The cleavage of lamin A by Mch2ac and by S/M
extracts was inhibited by millimolar concentrations of Zn2+,
which had a minimal effect on cleavage of poly(ADP-ribose)
polymerase by CPP32 and by S/M extracts. We also found that
N-(acetyltyrosinylvalinyl-N6-biotinyllysyl)aspartic acid [(2,
6-dimethylbenzoyl)oxy]methyl ketone, which derivatizes the
larger subunit of active ICE, can affinity label up to five active
IRPs in S/M extracts. Together, these observations indicate
that the processing of nuclear proteins in apoptosis involves
multiple IRPs having distinct preferences for their apoptosis-
associated substrates.
A key question in cell death research is whether the apoptotic
cascade is driven by the action of a single interleukin 1l3-
converting enzyme (ICE)-related protease (IRP) (1-7) or by
multiple IRPs acting in concert (8). In the nematode Caeno-
rhabditis elegans, a single IRP is required for all developmental
cell deaths (1, 9). In contrast, cDNA cloning experiments show
that at least seven IRP mRNAs are expressed in a single human
cell type (4, 7, 10, 11), raising the possibility that multiple IRPs
might be required for completion of apoptosis in vertebrates.
The individual roles of these multiple IRPs during apoptosis
are currently unclear.
To begin to address this question, we have compared
proteolytic cleavage of two apoptotic substrates by cloned IRPs
expressed in Escherichia coli and by cell-free extracts (named
S/M extracts, prepared from chicken DU249 hepatoma cells
committed to apoptosis by an S-phase aphidocolin block and
subsequently collected in M phase) (12, 13). Exogenous nuclei
incubated in S/M extracts recapitulate nuclear apoptotic
events, including endonucleolytic cleavage of DNA, chromatin
condensation, and fragmentation of the nucleus (12). Incuba-
tion of nuclei or purified poly(ADP-ribose) polymerase
(PARP) in S/M extracts results in rapid, quantitative cleavage
of the PARP to a 85-kDa fragment indistinguishable from that
observed in a wide variety of apoptotic cells (13-15). This
cleavage occurs at a conserved DEVDUG sequence and is
mediated by an enzyme with substrate recognition properties
and inhibitor sensitivity similar to ICE. We termed this
proteolytic activity prICE [protease(s) resembling ICE (13)].
Subsequent investigations have shown that the cloned human
IRPs CPP32, Mch2a, and Mch3a as well as the C. elegans
IRP CED-3 all cleave PARP (5, 7, 11, 16, 17). ICE itself can
also cleave a PARP subfragment when added in considerable
excess (18); however, at near physiological levels, it does not
cleave full-length native PARP (5, 13).
Although PARP was the first apoptosis-specific IRP sub-
strate to be identified, the physiological significance of PARP
cleavage in apoptosis is presently unknown (for review, see ref.
15). In contrast, cleavage of the nuclear lamins is a proteolytic
event that appears to be required for completion of nuclear
reorganization during apoptosis. Lamin A is cleaved in S/M
extracts (8) to fragments that are indistinguishable from those
produced in cells undergoing apoptosis (8, 19-21). The inhib-
itor profile of the lamin protease suggests that lamin cleavage
depends upon the activity of an IRP distinct from the PARP-
cleaving IRP (8). Inhibition of the lamin protease by Tos-Lys-
CH2Cl (TLCK) (8) or the serpin-like IRP inhibitor CrmA/
SPI-2 (A.T., P.-Y. Musy, G.G.P., R. W. Moyer, and W.C.E.,
unpublished work) abolishes nuclear fragmentation in vitro.
This has led to the speculation that activity of the lamin
protease may be a prerequisite for apoptotic nuclear disas-
sembly (8).
Despite these advances in our understanding of IRP activity
during apoptosis, it remains to be determined whether lamin
cleavage is directly catalyzed by an IRP and whether multiple
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IRPs are active in S/M extracts. Here we show that the human
IRP Mch2a (7) cleaves human lamin A at a conserved
sequence that corresponds to the site of lamin A cleavage in
S/M extracts. In contrast, CPP32 does not cleave lamin A
under conditions where it efficiently cleaves PARP. We also
show by direct affinity labeling that multiple IRPs with distinct
substrate recognition properties are active simultaneously in
S/M extracts. These experiments suggest that multiple IRPs
with different preferences for apoptotic substrates play distinct
roles in apoptotic execution.
MATERIALS AND METHODS
Assay of Protease Activity in E. coli Lysates Containing
Recombinant Human IRPs. Lysates from E. coli DH5a ex-
pressing CPP32a and Mch2a were prepared as described (7),
except that the E. coli lysis buffer was supplemented with
chymostatin, leupeptin, antipain, pepstatin, phenylmethylsul-
fonyl fluoride, and aprotinin. Purified recombinant human
lamin A (8), purified bovine PARP (13), and nuclei isolated
from HeLa S3 cells (12) were incubated with the E. coli lysates
at 37°C; substrate cleavage was analyzed by immunoblotting as
described (8, 13). To control for the effects of endogenous E.
coli proteases, the substrates were also incubated with lysates
from E. coli that were not transformed with plasmids or with
lysates from E. coli expressing Mch2,B, a catalytically inactive
truncated version of Mch2a (7). Autoradiographic films were
scanned using the COLLAGE software (Fotodyne, New Berlin,
WI) so that cleavage could be quantitated from the intensity
of the signals of uncleaved and cleaved substrates.
Mapping the Lamin A Cleavage Site. Lamin A (amino acids
1-463) tagged with (His)6 at its C terminus was purified using
Ni2+-agarose resin (Novagen) according to the manufacturer's
instructions. After 200 pmol of this substrate was incubated
with 1.25 mg of E. coli lysate expressing Mch2a for 120 min,
the cleaved C-terminal fragment was repurified on Ni2+_
agarose, subjected to SDS/PAGE, transferred to polyvinyli-
dene difluoride (PVDF) membrane (22), and microse-
quenced. The sequence revealed multiple amino acids at each
position, but after subtraction of the sequences of two bacterial
proteins that also bound the metal column [E. coli 30-kDa
protein (23) and E. coli curved DNA binding protein (24); both
are perfect 12/12 matches], the remaining sequence consisted
of N*K*REFESRL, a perfect match to positions 231-241 of
human lamin A.
Direct Labeling of Active IRPs in S/M Extracts. S/M
extracts were prepared from chicken DU249 cells as described
(12). N-(acetyltyrosinylvalinyl-N--biotinyllysyl)aspartic acid
[(2,6-dimethylbenzoyl)oxy]methyl ketone (25) [here termed
YV(bio)KD-aomk] was kindly provided by Nancy Thornberry
(Merck), dissolved in dimethyl sulfoxide (DMSO) at 10 mM,
and stored at -80°C. S/M extracts were incubated with
YV(bio)KD-aomk for 5 min at 37°C, subjected to SDS/PAGE
in 16% gels, transferred to nitrocellulose, probed with perox-
idase-labeled streptavidin, and visualized by the Enhanced
Chemiluminesence kit (Amersham).
Labeling and Quantitation of Active IRPs in E. coli Lysates.
Lysates (150 jig) from E. coli expressing CPP32a or Mch2a
and purified recombinant ICE (1.2 ng) (13) were incubated
with 10 ,uM of YV(bio)KD-aomk for 5 min at 37°C and
processed for detection of the bound biotin as described above
for S/M extracts. The bands corresponding to the larger
subunit of active CPP32a ('17 kDa), Mch2a (-19 kDa), and
ICE (-20 kDa) were scanned and their intensity was measured
using the COLLAGE software. The quantity of active IRP giving
a labeling intensity corresponding to that seen with 1 ng of
purified recombinant ICE was defined as "1 IRP unit." One
milligram of E. coli lysate containing CPP32a and Mch2a had
24 and 19 IRP units of active enzymes, respectively. When
defining the total number of IRP units in a given amount of
S/M extract, the labeling of all YV(bio)KD-aomk-labeled
bands corresponding to prICE1 swas determined. When de-
fining the number of PARP-cleaving IRP units in a given
amount of S/M extract, only the content of active prICE1 was
used, because this species appeared to have a much higher
affinity for the PARP cleavage site peptide than did prICE2-5.
RESULTS
Cleavage ofLaminA by Mch2a, but Not by CPP32. To assess
the possibility that lamins are cleaved by IRP(s) in apoptosis,
we examined the ability of cloned human IRPs to cleave lamin
A. E. coli lysates containing recombinant Mch2a, an IRP
resembling CED-3, cleaved purified recombinant human
lamin A (Fig. la, lane 4) to generate a fragment that comi-
grated with a fragment produced in S/M extracts (Fig. la, lane
3). In control experiments, lysates from untransformed E. coli
DH5a (Fig. la, lane 2) or from E. coli expressing the inactive
Mch2 splice variant Mch2f (Fig. la, lane 5) failed to cleave
lamin A. Lamin A cleavage by Mch2a was readily inhibited by
the IRP inhibitor Tyr-Val-Ala-Asp-CH2Cl (YVAD-cmk) (Fig.
lc), but not by a cocktail of other inhibitors that was routinely
included in the E. coli lysis buffer. This mixture contained
chymostatin, leupeptin, antipain, pepstatin, phenylmethylsul-
fonyl fluoride, and aprotinin. Mch2a also cleaved endogenous
human lamin A in HeLa nuclei (Fig. lb, lane 2). Again, the
lamin A fragment comigrated with a fragment observed in
apoptosis in vitro (Fig. lb, lane 4) and in vivo (8).
Not all IRPs involved in apoptosis are active against the
lamin substrate. CPP32, a second IRP homologous to CED-3,
appears to be incapable of cleaving lamin A (Fig. 1 a, lane 6,
and b, lane 3). After normalization of the amounts of active
enzymes in E. coli lysates (see Materials and Methods), the
proteolytic activities of Mch2a and CPP32 against different
substrates were compared. The rate of lamin A cleavage by
Mch2a was roughly comparable with that of S/M extracts,
whereas CPP32 failed to cleave this substrate (Fig. ld). The
converse was true for PARP cleavage. Initial rates of PARP
cleavage by CPP32 and S/M extract were essentially identical
(Fig. le). Although Mch2a does possess PARP cleavage
activity (7), this is considerably lower than the activity of
CPP32 against PARP (Fig. le). These results revealed that
Mch2a and CPP32 have distinct preferences for lamin A and
PARP, respectively.
Lamin A Cleavage Site. Peptide sequencing of the Mch2a
cleavage product from a purified recombinant human lamin A
subfragment (see Materials and Methods) revealed that cleav-
age occurred at D230 of lamin A (Fig. 2a). Alignment of lamin
A sequences available in the data bases revealed that this
cleavage site, which lies in the midst of the a-helical rod
domain, is well-conserved across species from mammals to
Drosophila (Fig. 2a).
We have used synthetic peptides to confirm that the
endogenous lamin protease in S/M extracts recognizes the
Mch2a cleavage site on lamin A. We synthesized an 11-mer
peptide corresponding to the lamin A cleavage site
(RLVEIDNGKQR) and a mutant peptide containing alanine
in place of aspartate (RLVEIANGKQR). The cleavage site
peptide inhibited lamin A cleavage by S/M extracts (Fig. 2b,
lane 3) and by Mch2a (data not shown), whereas the mutant
peptide had no effect (Fig. 2b, lane 4). The laminA peptide did
not affect PARP cleavage in S/M extracts (Fig. 2b, lane 3).
This result strongly suggests that Mch2a and the endogenous
lamin protease in S/M extracts cleave lamin A at the same
VEID'U'NG bond. Moreover, these results demonstrated a
requirement for aspartate at the PI position of the lamin
cleavage site, a characteristic of IRPs (26).
In a control experiment, we confirmed our previous finding
that cleavage of PARP in the apoptotic extracts could be
specifically inhibited by a peptide (GDEVDGIDEV) spanning
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FIG. 1. (a) Cleavage of recombinant human lamin A by Mch2a. Purified recombinant human lamin A (400 ng) (8) was incubated for 120 min
at 37°C with MDB buffer (10 mM Hepes, pH 7.0/40 mM B3-glycerophosphate/50 mM NaCl/2 mM MgCl2/5 mM EGTA/1 mM DTT) (12) (lane
1), with 30 ,g of lysate from untransformed E. coli DH5a (lane 2), with 70 ,ug S/M extract (12) (lane 3), or with 30 ,ug of lysate from E. coli expressing
cDNAs encoding Mch2a (7) (lane 4) or Mch2,B (lane 5). Lane 6, purified recombinant human lamin A (200 ng) was incubated for 150 min at 37°C
with 150 ,ug of E. coli lysate containing CPP32 (4, 7). (b) Cleavage of endogenous HeLa nuclear lamin A by Mch2a. HeLa nuclei (1 x 106) were
incubated at 37°C for 120 min with lysate from untransformed E. coli DH-5a (60 g.g) (lane 1) and from E. coli expressing Mch2a (120 ,g) (lane
2) or CPP32 (70 tg) (lane 3); with S/M extract (140 ,g) (lane 4); or with a combination of Mch2a lysate (120 p.g) plus S/M extract (140 ,ug) (lane
5). (c) A specific ICE inhibitor blocks cleavage of recombinant human A by Mch2a. E. coli lysates (30 ,g) expressing Mch2a were preincubated
with 1% DMSO or with 0.1, 1, 10, and 100 ,uM YVAD-cmk (Bachem) for 15 min at 37°C before addition of recombinant human lamin A and
incubation for 120 min. (d) Time course of lamin A cleavage by IRPs. Recombinant human lamin A was incubated as described in a for the times
indicated with lysate from E. coli expressing CPP32 (A) or Mch2a (O), or with S/M extracts (0). The amount of cleaved lamin A per IRP unit
of each active enzyme was calculated for each time point. (e) Time course of PARP cleavage by IRPs. Purified bovine PARP (200 ng) (13) was
incubated for the time indicated with 150 ,ug of lysate from E. coli expressing CPP32 (A) or Mch2a (m), or with 70 ,ug of S/M extracts (0). The
amount of cleaved PARP per IRP unit of each active enzyme was calculated for each time point.
the PARP cleavage site (13). This peptide had no detectable
effect on the efficiency of lamin A cleavage at concentrations
where it substantially lowered the efficiency ofPARP cleavage
(Fig. 2b, lane 5). PARP cleavage by CPP32 was inhibited by the
PARP cleavage site D peptide (Fig. 2b, lane 9) but only poorly
by the mutant A peptide (Fig. 2b, lane 10). Together, these
observations confirm that the endogenous lamin and PARP
proteases in S/M extracts have distinct substrate recognition
properties similar to those of Mch2a and CPP32.
Inhibition of Lamin A but Not PARP Cleavage by Zn2+.
Cleavage of purified recombinant human lamin A by Mch2a
(Fig. 3a) and by S/M extracts (Fig. 3b) was inhibited by Zn2+
in a dose-dependent manner. Zn2+ also blocks the cleavage of
endogenous nuclear lamin A in HeLa nuclei induced by S/M
extracts (Fig. 3b). Under these conditions, completion of
morphological apoptosis was also blocked (12).
In contrast, cleavage of purified bovine PARP catalyzed by
both recombinant CPP32 (Fig. 3a) and S/M extracts (Fig. 3b)
was relatively insensitive to Zn2+. A similar result was obtained
with endogenous nuclear human PARP (Fig. 3b).
Multiple Active IRPs in S/M Extracts. Our functional
studies reveal that S/M extracts contain at least two distinct
IRPs with differing substrate preferences and differing inhib-
itor profiles (Figs. 2b and 3b). To directly visualize these
enzymes, we set out to establish whether YV(bio)KD-aomk, a
probe that was developed to covalently derivatize the larger
subunit of active ICE but not its inactive proenzyme (25),
would also directly label other IRPs. Control experiments (Fig.
4b) indicated that 10 ,LM YV(bio)KD-aomk labels cloned
human CPP32 and Mch2a in E. coli extracts, indicating that
this reagent will react with the active sites of diverse IRPs in
addition to ICE. When this same approach was applied to S/M
extracts, up to five polypeptides of -19.5, 19, 18.5, 17.8, and
17.6 kDa were reproducibly labeled after reaction with 100 ,LM
YV(bio)KD-aomk (Fig. 4a, lane 1). All of these labeled species
differed in mobility from the p20 subunit of purified human
ICE (Fig. 4a, lanes 7 and 9). In keeping with our earlier
terminology, we have termed these bands prICE1l5. prICE1.5
exhibit a distinct hierarchy of labeling by YV(bio)KD-aomk.
prICE4 is labeled at 0.1 ,uM YV(bio)KD-aomk (Fig. 4a, lane
5), prICE1 and prICE5 are labeled at 1 ,uM (Fig. 4a, lane 4),
and prICE2 and prICE3 require 100 ,uM for labeling (Fig. 4a,
lane 1). This labeling hierarchy suggests that prICE1 s exhibit
a hierarchy of affinities for YV(bio)KD-aomk.
Several control experiments indicate that the labeled species
correspond to active IRPs. First, preincubation ofS/M extracts
with 100 ,uM YVAD-cmk, a broad spectrum inhibitor of IRPs
at this concentration, abolished the labeling of all five bands
(Fig. 4a, lane 2). Second, no labeled polypeptides were de-
tected in extracts from nonapoptotic cells (Fig. 4a, lane 8),
indicating that prICE1 s are active only in apoptotic cells.
Third, labeling required the addition of YV(bio)KD-aomk
(Fig. 4a, lane 6), thereby ruling out the trivial explanation that
the labeled species correspond to endogenous biotinylated
proteins. Finally, the labeled species roughly comigrate with
the large subunits of known human IRPs [17 kDa for CPP32
(4, 16); 19 kDa for Mch2a (7)]. No labeling was seen of species
in the size range expected for IRP precursors (30-50 kDa).
prICE1 can be distinguished from prICE2s by its affinity for
the PARP cleavage site peptide (13). The addition of this
peptide to S/M extracts markedly diminished the labeling of
prICE1 whilst leaving the labeling of prICE4 and prICE5
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FIG. 2. (a) The site of lamin A cleavage in the rod domain is widely
conserved across different species. The human sequence shown cor-
responds to the lamin A peptide used in b. (b) Use of peptide inhibitors
to confirm the PARP and lamin cleavage sites and to demonstrate the
differing specificities of the lamin and PARP proteases. Purified
bovine PARP (300 ng) alone (lanes 7-10) or in combination with
recombinant human lamin A (200 ng) (lanes 1-6) was incubated at
37°C for 15 min (lanes 7-10) or for 120 min (lanes 1-6) in MDB (lane
1 and 7); in S/M extract (75 ,ug) plus 4% DMSO (lane 2), plus 4 ,Ig/,ul
of lamin A cleavage site peptide (D peptide = RLVEIDNGKQR, lane
3) or plus 4 ,ulg/,l of mutant peptide (A peptide = RLVEIANGKQR,
lane 4); in S/M extract (66 ,ug) plus 1 ,ug/Iul of PARP cleavage site
peptide (D peptide = GDEVDGIDEV, lane 5) or plus 1 ,t.g/jl. of
mutant peptide (A peptide = GDEVAGIDEV, lane 6); in E. coli lysate
containing CPP32 (30 ,ug) plus 2% DMSO (lane 8), plus 2 ,ug/,ll of
PARP cleavage site peptide (D peptide, lane 9) or plus 2 tcg/ltI of
mutant peptide (A peptide, lane 10).
unchanged (Fig. 4c, lane 2). Under the conditions of this
experiment, labeling of prICE2 and prICE3 was not readily
observed. In a control experiment, the labeling of prICE1 was not
inhibited by the D > A mutant peptide (Fig. 4c, lane 3), which
does not inhibit PARP cleavage in S/M extracts (13). Together,
these results indicate that prICE1 has a greater affinity for the
PARP cleavage sequence than prICE4 and prICE5.
DISCUSSION
Accumulating evidence suggests that the cleavage of nuclear
lamins is a universal event in apoptosis in vivo (8, 19-21) and
in vitro (8). Here, we have shown that the CED-3-related
human IRP Mch2a cleaves lamin A. A second well-
characterized CED-3-related human IRP, CPP32, did not
cleave lamin A under conditions in which it readily cleaved
PARP. Thus, CPP32 alone cannot mediate all of the proteo-
lytic events essential for the apoptotic disintegration of nuclei
(8). Recombinant ICE was similarly inactive against lamin A
(unpublished data). Peptide sequencing revealed that the
cleavage by Mch2a occurs adjacent to a conserved asp residue
in the a-helical rod domain of lamin A. This cleavage could
potentially disrupt lamin-lamin interactions as well as inter-
actions of lamins with other nuclear components such as matrix
attachment regions on the DNA (27), the retinoblastoma gene
a.
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FIG. 3. Effects of Zn2+ on the substrate cleavage by IRPs. (a) Zn2+
inhibits cleavage of purified recombinant human lamin A by Mch2a
but not cleavage of purified PARP by cloned human CPP32. Purified
PARP (300 ng) (a) and purified recombinant human laminA (400 ng)
(E) were incubated with E. coli lysates (30 ,ug) containing CPP32 or
Mch2a, respectively, in the presence of ZnCl2 at the indicated con-
centrations. The E. coli lysates were previously dialyzed against MDB
lacking EGTA for 3 hr at 4°C (12). After incubation for 15 min (for
PARP cleavage) or 120 min (for lamin A cleavage), substrate cleavage
was quantitated from immunoblots similar to those shown in Fig. 1 d
and e. (b) Effects of Zn2+ on the cleavage of PARP and lamin A by
endogenous IRPs in S/M extracts. Dialyzed apoptotic S/M extracts
(140 ,ug) were incubated either with HeLa nuclei (1.5 x 106; solid
symbols) for 60 min at 37°C, or with a mixture of purified PARP and
lamin A (as in a; open symbols). Substrate cleavage was quantitated
from immunoblots as in a. 0, Purified bovine PARP; 0, human nuclear
PARP; El recombinant human lamin A; *, human nuclear lamin A.
product (28), the adenovirus EBB 19-kDa product (29), and
core histones (30).
The observation that a peptide corresponding to the site of
lamin A cleavage by Mch2a also inhibited lamin A cleavage in
S/M extracts strongly suggests that recombinant Mch2a and
the endogenous lamin protease in S/M extracts cleave lamin
A at the same site. Although these data are consistent with the
notion that Mch2a is responsible for lamin cleavage in apo-
ptotic cells, we cannot rule out the possibility that other novel
CED-3-related IRPs (T.F.-A. & E.S.A., unpublished work)
might also cleave the lamins.
Although further study is required to reveal the biological
relevance of the inhibition of lamin A cleavage by Zn2+, it is
worth noting that Zn2+ is known to be a modulator of
apoptosis in vivo. Zn2+ depletion has been associated with
enhanced apoptosis in the small intestine (31) and thymus (32)
of rodents as well as with induction of apoptosis in cultured
cells (33-36). Conversely, Zn2+ supplementation inhibits in-
ternucleosomal DNA fragmentation and morphological fea-
tures of apoptosis in vivo (34, 37-40) and in vitro (12, 41). The
targets for this suppression of apoptosis by Zn2+ remain
unclear, although apoptotic nucleases have been suggested as
possible candidates (42, 43). An alternative hypothesis is that
some of the effects of Zn2+ on apoptosis are exerted, at least
in part, through a modulation of the actions of IRPs such as
Mch2a. Consistent with this hypothesis, we have observed that
lamin cleavage by recombinant Mch2a is inhibited by milli-
molar concentrations of Zn2+. It has also been reported that
ICE activity is inhibited by Zn2+ at concentrations higher than
375 ,uM (44). Conversely, it is worth noting that the effects of
Zn2+ on apoptosis are unlikely to be mediated by effects on
CPP32, which was relatively insensitive to the cation.
Based on the observation that CPP32 and Mch2a can be
labeled with the active site titrant YV(bio)KD-aomk (25), we
have developed a procedure to directly visualize the spectrum
of IRPs that is activated during apoptosis. This procedure
labeled at least five distinct polypeptides in S/M extracts. We
termed these prICEI 5. These five labeled polypeptides all
correspond to active IRPs, because the labeling is abolished by
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FIG. 4. (a) Labeling of multiple active IRPs in apoptotic S/M extracts. YV(bio)KD-aomk (25) was added at the indicated concentration to 30
,ug ofS/M extract (lanes 1-7) or control real mitotic (i.e., nonapoptotic) extract (12) (lanes 8-10). In lanes 7, 9, and 10, extracts were supplemented
with 1.2 ng of purified ICE (13). In lane 2, S/M extract was preincubated with 100 ,uM YVAD-cmk at 37°C for 15 min to inactivate IRPs before
addition of YV(bio)KD-aomk. (b) YV(bio)KD-aomk labels active recombinant CPP32 and Mch2a. Lysates (150 gg) from untransformed E. coli(lane 4) or from E. coli expressing CPP32 (lane 1), Mch2a (lane 2), or Mch2f3 (lane 3) were incubated with 10 ALM of YV(bio)KD-aomk at 37°C
for 5 min and electrophoresed in a Tris-tricine gel (22). The strong background bands represent two streptavidin-binding proteins in E. coli that
are detected without labeling with YV(bio)KD-aomk. (c) Competitive inhibition of prICEI labeling by the PARP cleavage site peptide. Active IRPs
in 100 ,ug of S/M extract were labeled with 10 ,uM YV(bio)KD-aomk in the presence of 2% DMSO (lane 1), 2 gg/pl of PARP cleavage site D
peptide (13) (lane 2), or 2 ,ug/Iul of mutant A peptide (lane 3). prICE2 and prICE3 (that require 100 ,uM YV(bio)KD-aomk for labeling) were not
visualized in this experiment.
pretreatment of extracts with YVAD-cmk. The simplest inter-
pretation of these results is that S/M extracts contain at least
five distinct active IRPs. These could be the products of five
different genes or certain of the labeled species could be
produced by either alternative splicing of a common mRNA
transcript or alternative proteolytic processing of a primary
translation product. cDNA cloning studies have revealed that
Jurkat cells express at least seven different IRP genes (4, 7, 10,
11) and produce at least five alternatively spliced forms of the
ICE transcript (10).
Regardless of their origin, our further analysis revealed
functional distinctions between several of these enzymes. First,
the labeled species show a 100-fold range in apparent affinity
for YV(bio)KD-aomk, with prICE4 being labeled at concen-
trations as low as 0.1 ,uM and prICE2 and prICE3 being labeled
only at 100 ,uM. Second, preincubation of S/M extracts with
the PARP cleavage site peptide resulted in a preferential
decrease in the labeling of prICE1. Thus, among the major
prICE species, prICE1 appears to have a selective affinity for
the PARP cleavage site. It is therefore tempting to suggest that
prICE1 might be a PARP protease. In similar experiments, use
of the lamin peptide as an inhibitor brought about a selective
decrease in the labeling of prICE5, This result, together with the
results of IRP inhibition with the serpin-like inhibitor CrmA/
SPI2 suggest that prICE5 may have a selective affinity for the
lamin cleavage sequence (AT., P-Y. Musy, G.G.P., R. W. Moyer,
and W.C.E., unpublished work). The preferred substrates for
prICE24 remain to be determined.
These results show that the YV(bio)KD-aomk reagent can
directly label active apoptosis-associated IRPs in cell-free
extracts and that the substrate preferences of these labeled
IRPs can be analyzed using cleavage site peptides. This meth-
odology should be of significant utility in the future analysis of
apoptotic execution in a wide range of cell death events.
Our observations suggest that apoptotic execution in higher
eukaryotic cells involves the coordinated action of multiple
IRPs, each with a distinctive menu of preferred targets. To the
extent that expression of these IRPs differs between various
cell types, the cleavage of various substrates and the sensitivity
to various inhibitors might also vary. Instead of a single
CED-3-related "death protease" and a universal death path-
way, it is possible that different cell types might use a number
of subtly different alternative pathways (45). Such a mecha-
nism might provide important flexibility to the range of
cellular responses to environmental signals.
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